## Patent claims

## 1. Compounds of formula 1,

## in which

R1 is 1-4C-alkyl,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

R3 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or 1-4C-alkoxy which is completely or predominantly substituted by fluorine,

## or in which

R2 and R3 together are a 1-2C-alkylenedioxy group,

R4 is hydrogen, halogen, nitro, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,

R5 is hydrogen, 1-8C-alkyl, 3-7C-cycloalkyl or phenyl-1-4C-alkyl,

R6 is 1-4C-alkyl, phenyl-1-4C-alkyl, or Aryl-1-4C-alkyl, in which

Aryl is R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkoxy, trifluoromethyl or cyano,

R62 is 1-4C-alkoxy,

and in which either

R7 is 1-4C-alkyl, and

n is 1 or 2,

or

R7 is hydrogen, and

n is 1, 2 or 3,

the salts, the N-oxides of these compounds and the salts of the latter.

WO 2005/090345 PCT/EP2005/051204 - 32 -

- Compounds of formula 1 according to claim 1 in which 2.
- R1 is 1-4C-alkyl,
- is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy, or 1-2C-alkoxy which is completely R2 or predominantly substituted by fluorine,
- R3 is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy, or 1-2C-alkoxy which is completely or predominantly substituted by fluorine,
- R4 is hydrogen, 1-4C-alkyl, trifluoromethyl or 1-4C-alkoxy,
- is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or phenyl-1-4C-alkyl, R5
- R6 is 1-4C-alkyl, phenyl-1-4C-alkyl, or Aryl-1-4C-alkyl, in which
- is R61- and/or R62-substituted phenyl, in which Aryl
- R61 is 1-4C-alkoxy, trifluoromethyl or cyano,
- R62 is 1-4C-alkoxy,
- R7 is hydrogen or 1-4C-alkyl,
- is 1 or 2,

the salts, the N-oxides of these compounds and the salts of the latter.

- 3. Compounds of formula 1 according to claim 1 in which
- R1 is methyl,
- R2 is 1-2C-alkoxy,
- R3 is 1-2C-alkoxy,
- R4 is hydrogen,
- is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl or phenyl-1-4C-alkyl, R5
- R6 is 1-4C-alkyl, phenyl-1-4C-alkyl, or Aryl-1-4C-alkyl, in which
- is 1-4C-alkoxy-substituted phenyl, trifluoromethyl-substituted phenyl, cyano-substituted phenyl, Aryl or R61- and R62-substituted phenyl, in which
- R61 is 1-4C-alkoxy,
- R62 is 1-4C-alkoxy,

and in which either

- R7 is hydrogen or 1-4C-alkyl,
- is 1 or 2,

the salts, the N-oxides of these compounds and the salts of the latter.

- Compounds of formula 1 according to claim 1 in which 4.
- R1 is methyl,
- R2 is ethoxy,
- R3 is methoxy,
- R4 is hydrogen,
- R5 is hydrogen, methyl, ethyl, propyl, isopropyl, cyclohexyl or benzyl,
- R6 is methyl, ethyl, isopropyl, butyl, benzyl, 3-phenylpropyl, or Aryl-methyl, in which
- is 4-methoxyphenyl, 4-trifluoromethylphenyl, 4-cyanophenyl or 3,5-dimethoxyphenyl, Aryl

and in which either

WO 2005/090345

R7 is hydrogen or methyl, and

n is 1 or 2,

or

R7 is ethyl or isobutyl, and

n is 1,

the salts, the N-oxides of these compounds and the salts of the latter.

- 5. A compound of formula 1 according to any of the preceding claims, in which the hydrogen atoms in positions 4a and 10b are in the cis position relative to one another.
- 6. A compound of formula 1 according to any of the preceding claims which have with respect to the chiral centers the configuration shown in formulae (1\*) or (1\*\*):

- 7. A compound of formula 1 as claimed in claim 1 for treating diseases.
- 8. A pharmaceutical composition comprising one or more compounds of formula 1 as claimed in claim 1 together with customary pharmaceutical auxiliaries and/or excipients.
- 9. The use of a compound of formula 1 as claimed in claim 1 for producing pharmaceutical compositions for treating respiratory disorders and/or dermatoses.
- 10. A method for treating an illness treatable by the administration of a PDE3/4 inhibitor in a patient comprising administering to said patient in need thereof a therapeutically effective amount of a compound of formula 1 as claimed in claim 1.

WO 2005/090345 PCT/EP2005/051204

- 34 -

11. A method for treating airway disorders and/or dermatoses in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula 1 as claimed in claim 1.